Oncology

By their training, pharmacists are natural problem solvers, and our education has taught us how to use resources to find an answer and often a solution. The world is waiting for a pharmaceutical solution to coronavirus disease 2019 (COVID-19).

Because triple-negative breast cancer does not express receptors involved in most breast cancers, the investigative therapy could offer a much-needed option.

The mortality rates for complex cancer procedures was shown to differ significantly depending on whether the procedure took place at 1-star hospitals or 5-star hospitals.

Medical oncologists globally should not discontinue or delay anti-cancer treatment that may potentially impact overall survival during the COVID-19 pandemic.

Due to a robust immune system, young women have a lower response rate to immunotherapy.

Mortality rates from non-small cell lung cancer have significantly declined in the United States in recent years.

Four new subtypes of cells within triple-negative breast cancer have been uncovered, containing promising new therapeutic targets for the disease.

Patients with relapsed or refractory lymphomas may benefit from CAR-NK cell immunotherapy and Have fewer adverse events.

Cancer survivors’ lean body mass found to be lower than the general population, which was connected with prior abdominal or pelvic radiation.

Like so many other conferences and events, ASCO transitioned to an online format because of the coronavirus disease 2019 (COVID-19) outbreak.

Study shows significant genomic differences between tumors caused by different strains of human papillomavirus.

The combination of sintilimab, pemetrexed, and a platinum-based chemotherapy has shown promise for nonsquamous non-small cell lung cancer.

Human papillomavirus vaccine may reduce the chance of high-grade cervical intraepithelial neoplasis.

Study shows that an individual's response to immunotherapy can be predicted within weeks, based on increasing or decreasing levels of circulating tumor DNA.

Several recent studies presented at the virtual SGO 2020 Annual Meeting on Women’s Cancer looked into veliparib, a potential anticancer PARP inhibitor, for treatment of various types of ovarian cancer.

By using a non-invasive screening model, care providers can help catch and treat more cases of colorectal cancer, a new study suggests.

Study examines the effect of a low-calorie, plant-based diet combined with vitamin C in helping to kill cancer cells.

Cancer care providers have increasingly been using biosimilars on a case-by-case basis with patients.

The clinical trial of teclistamab sought to identify a recommended phase 2 dose for patients with RRMM, with multiple IV doses and priming doses explored.

A recent study evaluated the efficacy of venetoclax monotherapy in participants with relapsed or refractory chronic lymphocytic leukemia.

With the groundbreaking advancements in specialty pharmacy, it is important to recognize the uniqueness of these medications and their respective patient populations.

The American Cancer Society is renewing efforts to increase HPV immunization as COVID-19 threatens to slow cancer prevention progress.

In the United States, these findings would translate to more than 269,000 prevented breast cancer cases and nearly 44,000 prevented cases of ovarian cancer.

As the most accessible member of the health care team, the pharmacist can provide patients with cancer with the information and support necessary to get through what might be the most challenging time of their lives.

The approval represents the first for a second-line treatment for adult patients who progressed during or after first-line therapy.

“These new therapies allow for treatment without some of the traditional chemotherapy agents.”

A fully human monoclonal antibody, cemiplimab targets the immune checkpoint receptor PD-1 on T cells, blocking cancer cells from using the PD-1 pathway to suppress T-cell activation.

Officials with the FDA have approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.

Isatuximab-ifrc is the third monoclonal antibody approved for the treatment of R/R MM.

The rarity of disease states coupled with novel medication mechanisms and high costs lead to complexities in accessing treatment and optimizing outcomes.